Ashland Inc. (NYSE: ASH) is a Basic Materials company (Chemicals - Specialty) with a market capitalization of $3.4B. The Maz Rating grades it against the other companies in its sector.
About three months ago (August 17, 2026), Ashland Inc. had a Maz Rating of 3.21 out of 5 (B+, Buy), ranked against the other companies in its sector. Its strongest factor then was Momentum (4.55), among the strongest in its sector; its weakest was Valuation (1.59), more expensive than most of its sector. The other factors: Profitability 3.24 (around the middle of its sector); Financial Health 2.90 (around the middle of its sector); Growth 2.36 (below most of its sector). The current rating is for members: log in to see it.
At $74.15, Ashland Inc. trades at 820.7x trailing earnings, 1.8x sales and 1.8x book value, with an EV/EBITDA of 13.5. Over the last twelve months it generated about $1.9B of revenue and $4M of net income. It runs a gross margin of 30.1%, an operating margin of 5.5% and a net margin of 0.2%. It shows return on equity of 0.2%, return on invested capital of 0.9% and a free cash flow yield of 8.1%. On the balance sheet: a debt-to-equity ratio of 0.80 and a current ratio of 2.96. Over the past 52 weeks the share price ranged from $48.00 to $79.50, with a beta of 0.36.
Ashland Inc. pays a dividend yielding 2.26%, with 1900% of earnings paid out. Its Maz Dividend Score is 3.21 out of 5, ranked against the other dividend payers in its sector (Safety 2.47, Growth 2.93, Yield 3.72, Consistency 4.32).
25 Wall Street analyst ratings cover the stock: 16 Buy and 9 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Ashland Inc. operates as a global supplier of specialized chemicals and additives. Its business activities are structured into four main divisions: Life Sciences; Personal Care & Household; Specialty Additives; and Intermediates and Solvents. The Life Sciences segment delivers pharmaceutical formulations, encompassing controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and binding agents for tablets. It also offers nutritional compounds like thickeners, stabilizers, emulsifiers, and various additives, alongside nutraceutical items designed for weight management, joint comfort, gastrointestinal health, sports nutrition, and general well-being. Additionally, this division provides custom formulation services, toll processing, and particle engineering expertise. The Personal Care & Household division manufactures a diverse array of naturally derived, biodegradable, and high-performance ingredients for personal care products. Its offerings extend to solutions for oral hygiene, such as toothpastes, mouthwashes, denture cleansers, and general dental care. For household applications, it supplies nature-sourced rheology modifiers, biodegradable wetting agents for surfaces, advanced encapsulants, and specialized polymers. The Specialty Additives segment's portfolio includes rheology modifiers, agents for foam control, surfactants, wetting agents, pH neutralizers, and advanced ceramic materials, which find application in catalytic converters, environmental filters, components for ceramic capacitors, plasma display panels, and solar cells. Furthermore, it supplies ingredients for textile printing, thermoplastic metals, and alloys utilized in welding processes. The Intermediates and Solvents division is responsible for producing 1,4 butanediol and its associated derivatives, notably n-methylpyrrolidone. Ashland's diverse product portfolio serves clientele across numerous consumer and industrial sectors, including architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceuticals. The company, previously known as Ashland Global Holdings Inc., was established in Wilmington, Delaware, in 1924.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Ashland Inc. (ASH) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 41.2% / 30% · (Cash+Inv) / Mkt Cap (36m) 21.9% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 41.2% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 14.4% / 33% · Receivables / Mkt Cap (36m) 7.99% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 41.2% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 14.4% / 33.33% · Receivables / Mkt Cap (24m) 7.99% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 30.9% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 8.92% / 33.33% · Receivables / Avg Assets (4Q) 5.28% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 30.3% / 33.33% · (Cash+ST Inv) / Total Assets 10.6% / 33.33% · (Cash+Recv) / Total Assets 16.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
It depends on the standard you follow. As of September 2026, Ashland Inc. (ASH) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
No. Ashland Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
Ashland Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q4 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.